RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

February 18, 2021

Study Completion Date

December 22, 2021

Conditions
PTEN Gene MutationPTEN Hamartoma Tumor Syndrome
Interventions
DRUG

RAD001

"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."

DRUG

Placebo

"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."

Trial Locations (3)

44104

Cleveland Clinic, Cleveland

94305

Stanford University, Palo Alto

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Office of Rare Diseases (ORD)

NIH

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

PTEN Research

UNKNOWN

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Boston Children's Hospital

OTHER